Merrimack Pharmaceuticals (NASDAQ: MACK) is on The StockGuru Leader Board today. The stock closed up 10.81% on Monday.
Volume was 393,144 shares traded.
Join in on the Discussion about MACK: http://members.stockguru.com/stocks/mack/
About the Company:
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its proprietary Network Biology discovery platform to integrate the fields of engineering, biology, and computing to discover and develop therapeutics and diagnostics. Its product candidates include MM-398, a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, is in multiple ongoing Phase I and Phase II clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell receptor, is in multiple ongoing Phase I and Phase II clinical trials. The companys products also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; and MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; and Selexis SA. The company, formerly known as Atlantic BioPharmaceuticals, Inc., was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: email@example.com.
All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: Publisher@StockGuru.com or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070